NORBERT G RIEDEL
CIK 1161662 · EXECUTIVE CHAIRMAN OF THE BOD · last filed 2026-04-22
NORBERT G RIEDEL is an EXECUTIVE CHAIRMAN OF THE BOD who has filed 81 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing shows the insider exercised options covering $260.6K of ETON on Apr 22, 2026. Across all open-market trades the lifetime net is −$28.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $17.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$17.26M
8
81
-$28.05M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ETON | Director | 224,300 | $46.65 | $10.46M | $30.0K | 12 | 2026-04-22 |
| JAZZ | Director | 21,069 | $256.81 | $5.41M | -$3.30M | 18 | 2026-03-02 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 56,553 | $44.96 | $2.54M | $0 | 4 | 2024-06-07 |
| Aptinyx Inc. (APTX) Delisted | EXECUTIVE CHAIRMAN OF THE BOD | 650,265 | $0.06 | $39.7K | $366.4K | 13 | 2023-01-05 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 28,540 | $18.07 | $515.7K | $0 | 2 | 2021-06-14 |
| ARIAD PHARMACEUTICALS INC (ARIA) Delisted | Director | 0 | — | — | $0 | 8 | 2017-02-16 |
| BAX | Corporate Vice President | 56,689 | $24.41 | $1.38M | -$25.15M | 17 | 2013-01-18 |
| OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted | Director | 1,340 | — | — | $0 | 2 | 2008-06-13 |
Recent Filings
81 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-22 | ETON | Exer (M) | +32,155 | $260.6K | EDGAR |
| 2026-03-02 | JAZZ | Mixed | — | -$184.1K | EDGAR |
| 2026-02-27 | JAZZ | Notice (144) | −3,415 | -$655.7K | EDGAR |
| 2026-02-05 | ETON | Exer (X) | +30,000 | $132.6K | EDGAR |
| 2026-01-14 | ETON | Grant (A) | — | $0 | EDGAR |
| 2025-08-11 | JAZZ | Mixed | +1,702 | -$200.8K | EDGAR |
| 2025-08-08 | JAZZ | Notice (144) | −3,731 | -$417.9K | EDGAR |
| 2025-01-06 | ETON | Exer (M) | +102,400 | $373.8K | EDGAR |
| 2025-01-06 | ETON | Grant (A) | — | $0 | EDGAR |
| 2024-08-06 | JAZZ | Mixed | +2,247 | -$165.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.